Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy

Wendy J M van de Ven; J P Michiel Sedelaar; Marloes M G van der Leest; Christina A Hulsbergen-van de Kaa; Jelle O Barentsz; Jurgen J Fütterer; Henkjan J Huisman

doi:10.1016/j.clinimag.2016.02.005

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy

Clin Imaging. 2016 Jul-Aug;40(4):745-50. doi: 10.1016/j.clinimag.2016.02.005. Epub 2016 Feb 6.

Authors

Wendy J M van de Ven¹, J P Michiel Sedelaar², Marloes M G van der Leest³, Christina A Hulsbergen-van de Kaa⁴, Jelle O Barentsz³, Jurgen J Fütterer³, Henkjan J Huisman³

Affiliations

¹ Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: [email protected].
² Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
⁴ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 27317220
DOI: 10.1016/j.clinimag.2016.02.005

Abstract

Objectives: To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions.

Methods: Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores.

Results: TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component.

Conclusions: Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.

Keywords: Lesion visibility; MR-US fusion; PIRADS; Prostate cancer; Ultrasonography.

MeSH terms

Aged
Biopsy
Humans
Magnetic Resonance Imaging, Interventional / methods*
Male
Middle Aged
Multimodal Imaging / methods*
Neoplasm Grading
Observer Variation
Prostate / diagnostic imaging
Prostate / pathology
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / pathology*
Retrospective Studies
Ultrasonography, Interventional / methods*